All‐cause mortality at up to day 281 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 281 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
Admission to hospital or death within 28 days · non‐hospitalised adults with mild COVID‐19
Remdesivir and standard care probably leads to lower clinical worsening: participants admitted to hospital or deceased at… compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
Quality of life · non‐hospitalised adults with mild COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events at up to day 28 · non‐hospitalised adults with mild COVID‐19
Remdesivir and standard care may leads to lower serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
1 finding from 1 review
Adverse events: all grades · non‐hospitalised adults with mild COVID‐19
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
All‐cause mortality at up to day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 60 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
In‐hospital mortality at up to day 150 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in in‐hospital mortality at up to day 150 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care probably leads to higher clinical improvement: participants alive and ready to be discharged… compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
Clinical worsening: new need for invasive mechanical ventilation or death · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care probably leads to lower clinical worsening: time to new need for invasive mechanical… compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
Adverse events: all grades · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
1 finding from 1 review
Serious adverse events at up to day 28 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
1 finding from 1 review
All‐cause mortality at up to day 28 · non‐hospitalised adults with mild COVID‐19
1 finding from 1 review
Clinical improvement: participants with symptom alleviation at up to day 14 · non‐hospitalised adults with mild COVID‐19
It is very uncertain whether remdesivir and standard care changes clinical improvement: participants with symptom alleviation at up to… compared with standard care (plus/minus placebo) (very low certainty).
1 finding from 1 review
Intervention not reported
28‐day all‐cause mortality · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention probably leads to lower 28‐day all‐cause mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Quality of life up to longest · non‐hospitalised adults with mild COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Thrombotic events up to day 45 · non‐hospitalised adults with mild COVID‐19
The intervention showed no clear difference in thrombotic events up to day 45 (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events during study treatment · non‐hospitalised adults with mild COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events up to day 45 · non‐hospitalised adults with mild COVID‐19
The intervention showed no clear difference in serious adverse events up to day 45 (low certainty).
1 finding from 1 review
Intervention not reported
Major bleeding events up to longest · non‐hospitalised adults with mild COVID‐19
1 finding from 1 review
Intervention not reported
Worsening up to day 28: participants with new need for invasive mechanical ventilation or death · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention showed no clear difference in worsening up to day 28: participants with new need for invasive… (moderate certainty).
1 finding from 1 review